Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
- Registration Number
- NCT05011513
- Lead Sponsor
- Pfizer
- Brief Summary
The primary hypothesis to be tested is whether or not there is a difference in time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28 between PF-07321332/ritonavir and placebo.
- Detailed Description
Throughout the study period, provision will be made to allow study visits to be conducted at a participant's home or at another non-clinic location, if available. The total study duration is up to 24 weeks.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1440
- Confirmed SARS-CoV-2 infection 5 days prior to randomization
- Initial onset of COVID-19 signs/symptoms within 5 days of randomization
- Fertile participants must agree to use a highly effective method of contraception
- Has at least one underlying medical condition associated with an increased risk of developing severe illness from COVID-19
- History of or need for hospitalization for the medical treatment of COVID-19
- Prior diagnosis of SARS-CoV-2 infection (reinfection)
- Known medical history of liver disease
- Receiving dialysis or have known renal impairment
- Known Human Immunodeficiency Virus (HIV) infection with viral load > 400 copies/ml or taking prohibited medications for HIV treatment
- Suspected or confirmed concurrent active systemic infection other than COVID-19
- Current or expected use of any medications or substances that are highly dependent on Cytochrome P450 3A4 (CYP3A4) for clearance or are strong inducers of CYP3A4
- Has received or is expected to receive monoclonal antibody treatment or convalescent COVID-19 plasma
- Has received any SARS-CoV-2 vaccine within 12 months of screening
- Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19
- Known prior participation in this trial or other trial involving PF-07321332
- Oxygen saturation of < 92% on room air
- Females who are pregnant or breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PF-07321332/ritonavir PF-07321332 Orally administered PF-07321332+ritonavir PF-07321332/ritonavir Ritonavir Orally administered PF-07321332+ritonavir Placebo Placebo Orally administered Placebo
- Primary Outcome Measures
Name Time Method Time to Sustained Alleviation of Overall COVID-19 Signs and Symptoms Through Day 28 From Day 1 to Day 28 Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was considered as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this outcome measure time to sustained alleviation is reported consolidated for overall COVID-19 signs and symptoms.
- Secondary Outcome Measures
Name Time Method Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious AEs and AEs Leading to Study and Study Drug Discontinuation From start of study intervention (Day 1) up to Day 34 An AE was defined as any untoward medical occurrence in a participant or clinical study participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. An SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening ; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity ; congenital anomaly/birth defect; or that was considered as an important medical event. TEAEs were defined as events that started on or after the study medication start date and time. AEs included both serious and all non-serious adverse events. AEs that led to study discontinuation and AEs that led to discontinuation of study intervention and then continued study were also reported in this outcome measure.
Duration of Hospitalization and Intensive Care Unit (ICU) Stay Through Day 28 From Day 1 to Day 28 Percentage of Participants With Progression to Worsening Status of COVID-19 Signs and Symptoms From Day 1 to Day 28 Participants recorded a daily severity rating of their symptom severity over the past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe. Vomiting and diarrhea was rated on a 4-point frequency scale where 0 is reported for no occurrence, 1 (mild) for 1 to 2 times, 2 (moderate) for 3 to 4 times, and 3 (severe) for 5 or greater. Progression to a worsening status for any targeted symptom was based up on increasing severity (i.e. the first time any targeted symptoms worsened after treatment relative to baseline).
Percentage of Participants With COVID-19 Related Hospitalization or Death From Any Cause Through Day 28 From Day 1 to Day 28 Percentage of participants with COVID-19 related hospitalization or death from any cause during the first 28 days of the study was estimated using the Kaplan-Meier (KM) method.
Percentage of Participants With Death Through Week 24 From Day 1 to Week 24 Percentage of participants with death (all-cause) event were reported in this outcome measure.
Plasma Concentration Versus Time Summary of PF-07321332 Day 1: 1 hour post dose; Day 5: 0 minutes pre-dose Number of COVID-19 Related Medical Visits Per Day Through Day 28 From Day 1 to Day 28 Number of COVID-19 related medical visits per day were reported in this outcome measure.
Time to Sustained Resolution of Each COVID-19 Signs and Symptoms Through Day 28 From Day 1 to Day 28 Sustained resolution was defined as when targeted symptoms are scored as absent for 4 consecutive days. The first day of the 4 consecutive-day period was considered the first event date. In this outcome measure time to sustained resolution is reported consolidated for each COVID-19 signs and symptoms.
Percentage of Participants With Severe Signs and Symptoms of COVID-19 Through Day 28 From Day 1 to Day 28 Participants recorded a daily severity rating of their symptom severity over the past 24 hours based on a 4-point scale in which 0 was reported if no symptoms were present; 1 if mild; 2 if moderate; and 3 if severe. A participant with severe score for any targeted symptoms post-baseline was counted as severe. Vomiting and diarrhea each was rated on a 4-point frequency scale where 0 was reported for no occurrence, 1 for 1 to 2 times, 2 for 3 to 4 times, and 3 for 5 or greater. Sense of smell and sense of taste each be rated on a 3-point Likert scale where 0 was reported if the sense of smell/taste was the same as usual, 1 if the sense of smell/taste was less than usual, and 2 for no sense of smell/taste.
Time to Sustained Alleviation of Each COVID-19 Signs and Symptoms Through Day 28 From Day 1 to Day 28 Sustained alleviation of targeted COVID-19 signs/symptoms was defined as the event occurring on the first 4 consecutive days when all symptoms scored as moderate or severe at the time of enrollment were scored as mild or absent and those scored mild or absent at the time of enrollment were scored as absent. Missing severity at baseline was treated as mild. Time to sustained alleviation of all targeted COVID-19 signs and symptoms through Day 28, was calculated as time (days) from start of study intervention or placebo (Day 1) until sustained alleviation of all targeted COVID-19 associated signs and symptoms. In this outcome measure time to sustained alleviation is reported for each COVID-19 signs and symptoms.
Percentage of Participants With Resting Peripheral Oxygen Saturation Greater Than or Equal to (>=) 95% at Day 1 and Day 5 Day 1 and Day 5 Percentage of participants with a resting peripheral oxygen saturation \>=95% were reported in this outcome measure.
Time to Sustained Resolution of Overall COVID-19 Signs and Symptoms Through Day 28 From Day 1 to Day 28 Sustained resolution was defined as when targeted symptoms are scored as absent for 4 consecutive days. The first day of the 4 consecutive-day period was considered the first event date.
Change From Baseline in Logarithm to Base10 (Log10) Transformed Viral Load at Days 3, 5, 10 and 14 Baseline, Days 3, 5, 10 and 14 Nasal samples were collected to estimate the viral load in participants in terms of logarithm to base 10 (log10) copies per milliliter.
Trial Locations
- Locations (220)
Eastern Research Inc
šŗšøHialeah, Florida, United States
Premium Medical Research Corp
šŗšøMiami, Florida, United States
South Florida Research Center, Inc.
šŗšøMiami, Florida, United States
I.V.A.M. Clinical & Investigational Center, LLC
šŗšøMiami, Florida, United States
Entrust Clinical Research
šŗšøMiami, Florida, United States
Clinical Site Partners, Inc d/b/a CSP Miami
šŗšøMiami, Florida, United States
Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University,
š¹šHat Yai, Songkhla, Thailand
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT),
š¹šPathumwan, Bangkok, Thailand
Centro de Estudos e Pesquisas em MolƩstias Infecciosas
š§š·Natal, RIO Grande DO Norte, Brazil
Siriraj Hospital, Mahidol University
š¹šBangkokNoi, Bangkok, Thailand
Ahmed Al-Kadi Private Hospital
šæš¦Mayville, Durban, Kwazulu-natal, South Africa
Chronos Pesquisa Clinica
š§š·Brasilia, Distrito Federal, Brazil
Centro de Investigacion en Reumatologia y Especialidades Medicas S.A.S, CIREEM S.A.S
šØš“Bogota, Cundinamarca, Colombia
CEMEC - Centro Multidisciplinar de Estudos ClĆnicos
š§š·SĆ£o Bernardo do Campo, SĆO Paulo, Brazil
Fundacion Centro de Investigacion Clinica CIC
šØš“Medellin, Antioquia, Colombia
Fundacion Cardiomet Cequin
šØš“Armenia, Quindio, Colombia
Christus - Latam Hub Center of Excellence and Innovation Center S.C.
š²š½Monterrey, Nuevo LEON, Mexico
Oaxaca Site Management Organization
š²š½Oaxaca de Juarez, Oaxaca, Mexico
AsociaciĆ³n Mexicana para la InvestigaciĆ³n ClĆnica A.C.
š²š½Pachuca de Soto, Hidalgo, Mexico
Eukarya Pharmasite S.C.
š²š½Monterrey, Nuevo LEON, Mexico
ALERGIA s.r.o.
šøš°Topolcany, Slovakia
Instituto MĆ©dico de la FundaciĆ³n Estudios ClĆnicos (FundaciĆ³n Estudios ClĆnicos)
š¦š·Rosario, Santa FE, Argentina
HODOSI - MED, s.r.o.
šøš°Moldava nad Bodvou, Slovakia
Global Clinical Trials
šæš¦Gqeberha, Eastern CAPE, South Africa
Hospital Taiping
š²š¾Taiping, Perak, Malaysia
Kohler & Milstein Research S.A. De C.V.
š²š½Merida, Yucatan, Mexico
MUDr. Viliam Cibik, PhD., s.r.o.
šøš°Pruske, Slovakia
South Bay Clinical Research Institute
šŗšøRedondo Beach, California, United States
Lightship
šŗšøEl Segundo, California, United States
Ark Clinical Research
šŗšøLong Beach, California, United States
McFarland Clinic, PC
šŗšøAmes, Iowa, United States
Synergy Healthcare
šŗšøBradenton, Florida, United States
Unlimited Medical Research Group, LLC
šŗšøHialeah Gardens, Florida, United States
Inpatient Research Clinic
šŗšøHialeah, Florida, United States
AXCES Research Group
šŗšøSanta Fe, New Mexico, United States
Tranquility Research
šŗšøWebster, Texas, United States
Excel Clinical research
šŗšøLas Vegas, Nevada, United States
South Texas Clinical Research
šŗšøCorpus Christi, Texas, United States
Mercury Street Medical Group, PLLC
šŗšøButte, Montana, United States
Southern Clinical Research Associates, LLC
šŗšøMetairie, Louisiana, United States
Innovo Research: Wilmington Health
šŗšøWilmington, North Carolina, United States
SignatureCare Emergency Center
šŗšøHouston, Texas, United States
Trio Clinical Trials, LLC
šŗšøHouston, Texas, United States
Next Level Urgent Care
šŗšøHouston, Texas, United States
LinQ Research, LLC
šŗšøPearland, Texas, United States
Conroe Willis Medical Research
šŗšøConroe, Texas, United States
PharmaTex Research, LLC
šŗšøAmarillo, Texas, United States
St Hope Foundation
šŗšøBellaire, Texas, United States
Clinica de Alergia Martti Antila
š§š·Sorocaba, SĆO Paulo, Brazil
CECIP JAĆ - Centro de Estudos ClĆnicos do Interior Paulista - LTDA
š§š·Jau, SAO Paulo, Brazil
DCC Sveti Georgi EOOD
š§š¬Plovdiv, Bulgaria
MOBAL "D-r Stefan Cherkezov" AD
š§š¬Veliko Tarnovo, Bulgaria
Varosmajori Sziv- es Ergyogyaszati Klinika
ššŗBudapest, Hungary
Agria-Study Kft.
ššŗEger, Hungary
Hospital Miri
š²š¾Miri, Sarawak, Malaysia
Sociedad de Metabolismo y Corazon S.C.
š²š½Veracruz, Mexico
Centrum BadaÅ Klinicznych Piotr Napora Lekarze SpĆ³Åka Partnerska
šµš±Wroclaw, Poland
Clinical Trial Systems (Pty) Ltd
šæš¦Pretoria, Gauteng, South Africa
Be Part Research Pty (Ltd)
šæš¦Paarl, Western CAPE, South Africa
Lenasia Clinical Trial Centre
šæš¦Johannesburg, Gauteng, South Africa
Eba Centelles
šŖšøCentelles, Barcelona [barcelona], Spain
Khon Kaen Univerisity Field Hospital, Student Dormitory 26, Khon Kaen University
š¹šKhon Kaen, Thailand
Acibadem University Atakent Hospital
š¹š·Istanbul, Turkey
Thai Red Cross Emerging Infectious Diseases (EDI) Clinic
š¹šPathumwan,, Bangkok, Thailand
Istanbul University Istanbul Medical Faculty
š¹š·Istanbul, Turkey
Riverside Bangkok Hotel
š¹šBangplud, Bangkok, Thailand
Bangkok Centre Hotel
š¹šBangrak, Bangkok, Thailand
Baiyoke Suite Hotel
š¹šRatchathewi, Bangkok, Thailand
Cukurova University Medical Faculty
š¹š·Balcali, Adana, Turkey
Ankara University Medical Faculty, Ibni-Sina Hospital
š¹š·Ankara, Turkey
Hacettepe University Medical Faculty Hospital
š¹š·Ankara, Turkey
Municipal Nonprofit Enterprise of Kharkiv Regional Council "Regional Clinical Infectious Diseases
šŗš¦Kharkiv, Ukraine
Municipal Non-commercial Enterprise "Vinnytsia City Clinical Hospital ā1"
šŗš¦Vinnytsia, Ukraine
Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty
š¹š·Istanbul, Turkey
Medipol Mega University Hospital
š¹š·Istanbul, Turkey
Basaksehir Cam ve Sakura Sehir Hastanesi
š¹š·Istanbul, Turkey
Izmir Suat Seren Chest Disease and Surgery Training and Research Hospital
š¹š·Izmir, Turkey
Kocaeli University Medical Faculty
š¹š·Kocaeli, Turkey
Mersin University Medical Faculty
š¹š·Mersin, Turkey
Sakarya University Training and Research Hospital
š¹š·Sakarya, Turkey
Karadeniz Teknik Universitesi Farabi Hastanesi
š¹š·Trabzon, Turkey
IMED Valencia
šŖšøBurjassot, Valencia, Spain
Hospital Universitario de la Paz
šŖšøMadrid, Spain
Complexo Hospitalario Universitario da Coruna
šŖšøA CoruƱa, Spain
Savin Medical Group, LLC
šŗšøMiami Lakes, Florida, United States
Angels Clinical Research Institute
šŗšøMiami, Florida, United States
Global Health Clinical Trials Corp
šŗšøMiami, Florida, United States
C'A Research
šŗšøMiami, Florida, United States
Reed Medical Research
šŗšøMiami, Florida, United States
Clinical Site Partners, Inc. dba CSP Orlando
šŗšøWinter Park, Florida, United States
CDC Research Institute
šŗšøPort Saint Lucie, Florida, United States
Sunrise Research Institute
šŗšøSunrise, Florida, United States
Hope Clinical Research
šŗšøCanoga Park, California, United States
JM Research SC
š²š½Cuernavaca, Morelos, Mexico
ASCLEPES Research Centers
šŗšøSpring Hill, Florida, United States
Avera McKennan Hospital & University Health Center
šŗšøSioux Falls, South Dakota, United States
Doral Medical Research, LLC
šŗšøHialeah, Florida, United States
ProLive Medical Research, Corp.
šŗšøMiami, Florida, United States
The Institute for Liver Health dba Arizona Clinical Trials
šŗšøTucson, Arizona, United States
Cahaba Research Inc
šŗšøPelham, Alabama, United States
Ascada Research
šŗšøFullerton, California, United States
Matrix Mobile Health Clinic #49, #35, and #62
šŗšøScottsdale, Arizona, United States
TrueBlue Clinical Research
šŗšøBrandon, Florida, United States
Future Innovative Treatments, LLC
šŗšøColorado Springs, Colorado, United States
Hope Clinical Research (COVID Satellite Site)
šŗšøWest Hills, California, United States
Beautiful Minds Clinical Research Center
šŗšøCutler Bay, Florida, United States
Herco Medical and Research Center Inc
šŗšøCoral Gables, Florida, United States
MOORE Clinical Research, Inc.
šŗšøBrandon, Florida, United States
Advance Clinical Research Group
šŗšøCutler Bay, Florida, United States
LCC Medical Research Institute, LLC
šŗšøMiami, Florida, United States
Pro-Care Research Center, Corp.
šŗšøMiami Gardens, Florida, United States
Kendall South Medical Center, Inc.
šŗšøMiami, Florida, United States
Coral Research Clinic Corp
šŗšøMiami, Florida, United States
USPA Advance Concept Medical Research Group LLC
šŗšøSouth Miami, Florida, United States
GCP, Global Clinical Professionals
šŗšøSaint Petersburg, Florida, United States
Accellacare
šŗšøWilmington, North Carolina, United States
New Orleans Sinus Center (COVID-19 Testing)
šŗšøMarrero, Louisiana, United States
NYC Health + Hospitals / Harlem
šŗšøNew York, New York, United States
Tandem Clinical Research GI, LLC
šŗšøMarrero, Louisiana, United States
Monroe Biomedical Research
šŗšøMonroe, North Carolina, United States
Avera Research Institute
šŗšøSioux Falls, South Dakota, United States
Epic Medical Research
šŗšøRed Oak, Texas, United States
Instituto de Investigaciones Clinicas Zarate
š¦š·Zarate, Buenos Aires, Argentina
TPMG Clinical Research
šŗšøNewport News, Virginia, United States
TMPG Clinical Research
šŗšøNewport News, Virginia, United States
Hospital de Clinicas Presidente Nicolas Avellaneda
š¦š·San Miguel de Tucuman, Tucuman, Argentina
Hospital Privado Centro MĆ©dico de CĆ³rdoba
š¦š·CĆ³rdoba, Argentina
Clinica Mayo Urgencias Medicas Cruz Blanca SRL
š¦š·San Miguel de Tucuman, Tucuman, Argentina
Hospital De Clinicas De Porto Alegre
š§š·Porto Alegre, RIO Grande DO SUL, Brazil
Hospital Agamenon Magalhaes
š§š·Recife, Pernambuco, Brazil
IBPClin - Instituto Brasil de Pesquisa ClĆnica
š§š·Rio de Janeiro, RJ, Brazil
Instituto Nacional de Infectologia Evandro Chagas - INI/FIOCRUZ
š§š·Rio de Janeiro, RJ, Brazil
CECOR - Centro OncolĆ³gico de Roraima
š§š·Boa Vista, Roraima/rr, Brazil
Hospital Dia do Pulmao
š§š·Blumenau, SC, Brazil
Hospital AlemĆ£o Oswaldo Cruz
š§š·SĆ£o Paulo, SP, Brazil
Hospital e Maternidade Celso Pierro - PUC Campinas / Sociedade Campineira de EducaĆ§Ć£o e InstruĆ§Ć£
š§š·Campinas, SP, Brazil
Instituto de Infectologia Emilio Ribas
š§š·SĆ£o Paulo, Brazil
Unidade Referenciada Oswaldo Cruz Vergueiro
š§š·SĆ£o Paulo, SP, Brazil
Individual Practice for Primary Medical Care - IPPMC - Dr. P. Panayotov EOOD
š§š¬Burgas, Bulgaria
"Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases-Haskovo" Ltd
š§š¬Haskovo, Bulgaria
MHAT "Sv.Ivan. Rilski'' Kozloduy EOOD
š§š¬Kozloduy, Bulgaria
Diagnostic-Consultative Center I Lom EOOD
š§š¬Lom, Bulgaria
Multiprofile Hospital for Active Treatment- Sveti Nikolay Chudotvoretz EOOD
š§š¬Lom, Bulgaria
MHAT Heart and Brain EAD
š§š¬Pleven, Bulgaria
Medical centre Leo Clinic EOOD
š§š¬Lovech, Bulgaria
MHAT "St. Panteleimon "- Plovdiv
š§š¬Plovdiv, Bulgaria
Medical Center-1-Sevlievo EOOD
š§š¬Sevlievo, Bulgaria
"Specialized Hospital for Active Treatment of Pneumo-Physiatric Diseases Dr. Dimitar Gramatikov -
š§š¬Ruse, Bulgaria
Multiprofile Hospital for Active Treatment Sveti Ivan Rilski - Razgrad AD
š§š¬Razgrad, Bulgaria
Multiprofile hospital for active treatment - Sliven to Military Medical Academy
š§š¬Sliven, Bulgaria
Diagnostic-Consultative Center XXII- Sofia ŠŠŠD
š§š¬Sofia, Bulgaria
Multiprofile Hospital for Active Treatment - Samokov EOOD
š§š¬Samokov, Bulgaria
UMHATEM N. I. Pirogov EAD
š§š¬Sofia, Bulgaria
MHAT "St. Sofia" EOOD
š§š¬Sofia, Bulgaria
Specialized hospital for active treatment in pulmonology and phthisiology "Stara Zagora" EOOD
š§š¬Stara Zagora, Bulgaria
Multiprofile Hospital for Active Treatment Targovishte AD
š§š¬Targovishte, Bulgaria
Outpatient Clinic for Primary Outpatient Medical Care "Puls" - Dr. Mladen Buchvarov EOOD
š§š¬Tsarevo, Bulgaria
Medical center Leo Clinic EOOD
š§š¬Varna, Bulgaria
Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases Vratsa EOOD
š§š¬Vratsa, Bulgaria
ZdravĆ-Fit, s.r.o.
šØšæProtivĆn, Czechia
Semmelweis University Varosmajori Sziv Es Ergyogyaszati Klinika
ššŗBudapest, Hungary
Nemocnice Slany
šØšæSlany, Czechia
Trial Pharma Kft.
ššŗGyula, Hungary
International University of Health and Welfare Narita Hospital
šÆšµNarita, Chiba, Japan
Medifarma-98 Kft.
ššŗNyiregyhaza, Hungary
Debreceni Egyetem Klinikai Kozpont Infektologiai Klinika
ššŗDebrecen, Hungary
Rakuwakai Otowa Hospital
šÆšµKyoto-shi, Kyoto, Japan
Sekino Hospital
šÆšµToshimaku, Tokyo, Japan
Tokyo Shinagawa Hospital
šÆšµShinagawa-ku, Tokyo, Japan
Kyushu Medical Center
šÆšµFukuoka, Japan
Chonnam National University Bitgoeul Hospital
š°š·Gwangju, Korea, Republic of
Boramae Medical Center
š°š·Seoul, Korea, Republic of
SMG-SNU Boramae Medical Center
š°š·Seoul, Korea, Republic of
Hospital Raja Perempuan Zainab II
š²š¾Kota Bharu, Kelantan, Malaysia
Klinik Kesihatan Kuang
š²š¾Rawang, Selangor, Malaysia
Clinical Research Institute S.C.
š²š½Saltillo, Coahuila, Mexico
Instituto de Investigaciones ClĆnicas para la Salud
š²š½Durango, Mexico
FAICIC Clinical Research
š²š½Veracruz, Mexico
Tomasz Blicharski Lubelskie Centrum Diagnostyczne
šµš±Swidnik, Poland
Clinical Research Management Group Inc
šµš·Ponce, Puerto Rico
Advance Medical Research Center
šµš·San Juan, Puerto Rico
KLIMED Marek Klimkiewicz
šµš±Bialystok, Poland
Delta Health Care srl
š·š“Bucuresti, Romania
Worthwhile Clinical Trials
šæš¦Benoni, Gauteng, South Africa
Plucna ambulancia Hrebenar, s.r.o.
šøš°Spisska Nova Ves, Slovakia
Reimed Vosloorus
šæš¦Boksburg, Gauteng, South Africa
Botho Ke Bontle Health Services
šæš¦Pretoria, Gauteng, South Africa
Sandton Medical Clinic
šæš¦Sandton, Gauteng, South Africa
FCRN Clinical Trial Centre
šæš¦Vereeniging, Gauteng, South Africa
Dr PJ Sebastian Clinical Research Centre
šæš¦Durban, Kwa-zulu Natal, South Africa
Synapta Clinical Research Center
šæš¦Durban, Kwazulu Natal, South Africa
Hospital Universitari Germans Trias i Pujol
šŖšøBadalona, Barcelona, Spain
Srinagarind Hospital
š¹šKhon Kaen, Thailand
Hospital Universitario Virgen de Valme
šŖšøSevilla, Spain
Akdeniz Universitesi Hastanesi
š¹š·Antalya, Turkey
Gaziantep Universitesi Tip Fakultesi Sahinbey Uygulama ve Arastirma Hastanesi
š¹š·Gaziantep, Turkey
Municipal Nonprofit Enterprise "Ivano-Frankivsk Regional Clinical Infectious Diseases Hospital of
šŗš¦Ivano-Frankivsk, Ukraine
Regional Communal Nonprofit Institution "Chernivtsi Regional Clinical Hospital"
šŗš¦Chernivtsi, Ukraine
Communal non-commercial Enterprise "City Clinical Hospital ā3" of Chernivtsi City Council
šŗš¦Chernivtsi, Ukraine
Communal nonprofit enterprise "Central City Clinical Hospital of Ivano-Frankivsk City Council"
šŗš¦Ivano-Frankivsk, Ukraine
Municipal non-commercial enterprise "Kyiv City Clinical Hospital #1" Of Executive Body Of the Kyiv
šŗš¦Kyiv, Ukraine
Municipal Non-profit Enterprise "Oleksandrivska Kyiv City Clinical Hospital" Of Executive Body Of
šŗš¦Kyiv, Ukraine
Kyiv Railway Clinical Hospital No.2 of Branch "Health Center of the Public Joint Stock Company
šŗš¦Kyiv, Ukraine
Polyclinic of Center for Medical Services and Rehabilitation of State Joint-Stock Holding Company
šŗš¦Kyiv, Ukraine
Communal Enterprise "Hospital #1" of Zhytomyr City Council
šŗš¦Zhytomyr, Ukraine
WIP Warsaw IBD Point Profesor Kierkus
šµš±Warszawa, Poland
Municipal Non-profit Enterprise "Ivano-Frankivsk Regional Phthisiopulmonology Center of
šŗš¦Ivano-Frankivsk, Ukraine
Municipal Nonprofit Enterprise "Lviv City Clinic Hospital #4"
šŗš¦Lviv, Ukraine
Municipal Enterprise "Poltava Regional Clinical Infectious Diseases Hospital" of Poltava Regional
šŗš¦Poltava, Ukraine
Atella Clinical Research LLC.
šŗšøLa Palma, California, United States
Benchmark Research
šŗšøSacramento, California, United States
Optimus Medical Group
šŗšøSan Francisco, California, United States
Omega Research Orlando, LLC
šŗšøOrlando, Florida, United States
Santos Research Center, CORP
šŗšøTampa, Florida, United States
ARC Clinical Research at William Cannon
šŗšøAustin, Texas, United States
Endeavor Clinical Trials, LLC
šŗšøSan Antonio, Texas, United States
BFHC Research
šŗšøSan Antonio, Texas, United States
EME RED Hospitalaria
š²š½MĆ©rida, YucatĆ”n, Mexico
TASK Eden
šæš¦George, Western CAPE, South Africa
Hospital Alvaro Cunqueiro
šŖšøVigo, Pontevedra, Spain